
With increasing awareness of transthyretin amyloid cardiomyopathy (ATTR-CM) as a cause of heart failure and the availability of disease-modifying therapies, the importance of early diagnosis has grown. Consequently, greater emphasis has been placed on genetic testing and family screening to identify individuals with variant transthyretin amyloidosis (ATTRv) who are at risk of developing ATTRv cardiomyopathy (ATTRv-CM). To identify individuals with a genetic predisposition to the disease, all individuals with ATTR-CM should undergo genetic testing with subsequent cascade genetic testing in relatives when a genetic variant is identified. In asymptomatic pathogenic/likely pathogenic (P/LP) transthyretin (TTR) variant carriers, structured follow-up is recommended to enable early diagnosis, allowing timely initiation of treatment. Additionally, systematic family screening protocols may also help identify and detect ATTR-CM in general, including wild-type ATTR-CM.In conclusion, this narrative review provides clinicians with an overview of how to manage patients with ATTRv-CM and their families. Indeed, comprehensive genetic and cascade screening strategies are essential for early identification and optimal management of ATTR-CM. Future perspectives include refinement of risk stratification, optimization of diagnostic and screening pathways, improved timing of treatment initiation, and addressing health inequalities to ensure equitable access to care.
Transthyretin amyloid cardiomyopathy (ATTR-CM), once considered a rare disease, is now an increasingly recognized cause of heart failure. This rise in diagnoses is driven by increased awareness, the availability of non-invasive diagnostics, and the introduction of disease-modifying therapies (DMTs) in an aging population. Available DMTs are costly and may require 12 to 18 months before clinical benefit becomes apparent, making careful assessment of expected treatment benefit essential. Because ATTR-CM predominantly affects older adults, frailty, multimorbidity, and competing health risks are common. Frailty is associated with poorer outcomes and reduced quality of life, yet is not captured by current prognostic staging systems, which primarily reflect cardiac disease severity. Frailty assessment may complement cardiac evaluation by supporting personalized DMT decision-making and identifying modifiable vulnerabilities for targeted interventions. This narrative review integrates cardiology and geriatric perspectives to examine the role of Comprehensive Geriatric Assessment, including frailty assessment, in ATTR-CM. Evidence on frailty prevalence, prognostic significance, and the concept of a disease-specific frailty phenotype is summarized. The role and key components of the CGA are outlined. Additionally, a multidisciplinary care pathway incorporating CGA into clinical practice is proposed to support personalized DMT decisions and targeted interventions.
Arrhythmias are common in transthyretin amyloid cardiomyopathy (ATTR-CM) and contribute substantially to morbidity at all disease stages. The arrhythmogenic substrate—reflecting diffuse amyloid infiltration, atrial myopathy, autonomic dysfunction, and conduction system involvement—differs fundamentally from that in other cardiomyopathies. Prospective rhythm monitoring reveals a burden substantially higher than previously recognised and predominantly asymptomatic, with bradyarrhythmias and atrial fibrillation (AF) dominating and sustained ventricular arrhythmias remaining rare. This review examines key aspects of arrhythmia management in ATTR-CM. Conduction system disease is frequently encountered, and pacing strategies—including conduction system pacing—are discussed in the context of progressive infiltrative disease. We address the rationale for lifelong anticoagulation in AF irrespective of CHA2DS2-VA-score, and emerging considerations for anticoagulation in selected sinus rhythm patients with impaired atrial function. Rhythm control strategies are reviewed in light of extensive atrial substrate, high AF recurrence rates, and the absence of randomised trial data. The role of implantable cardioverter-defibrillators is examined, with emphasis on the lack of proven survival benefit for primary prevention. Finally, we explore disease-modifying therapies and their potential to attenuate the arrhythmogenic substrate. Overall, structured surveillance, rhythm control, and individualised device decisions form the cornerstones of modern arrhythmia management in ATTR-CM.
Amyloidosis comprises a group of systemic disorders caused by extracellular deposition of misfolded precursor proteins, leading to progressive organ dysfunction. Cardiac amyloidosis, particularly transthyretin-related amyloid cardiomyopathy (ATTR-CM) has transitioned from a rare and underdiagnosed condition to a treatable disease, driven by major advances in diagnostic imaging, increased disease awareness, and the approval of disease-modifying therapies. These therapies target transthyretin (TTR) stabilization and amyloid production or deposition and have led to an evolving therapeutic landscape. As therapeutic efficacy is greatest in earlier disease stages, timely recognition is crucial. Effective management of ATTR-CM requires structured screening of high-risk populations, multidisciplinary collaboration, and longitudinal follow-up. This review provides a practical, clinician-focused framework that addresses clinical presentation and “red flags” to facilitate early detection. It offers a comprehensive overview of the diagnostic pathway, including (AI-enabled) electrocardiography analysis, (non-)invasive imaging modalities, biomarkers, and genetic testing. Additionally, emerging therapeutic strategies are discussed, encompassing supportive heart failure management, amyloid-specific treatments such as TTR stabilizers and gene silencers, and novel approaches including fibril depletion and gene-editing therapies. As the therapeutic paradigm shifts from disease stabilization toward potential reversal, early diagnosis and personalized treatment strategies are essential to improve prognosis and quality of life in patients with cardiac amyloidosis.